Picture loading failed.

Anti-CD276;CD3E therapeutic antibody (Pre-made Obrindatamab biosimilar,Bispecific scFv with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Obrindatamab (formerly orlotamab) was a Fc-bearing humanised bispecific dual-affinity re-targeting (DART) protein, that was being developed by MacroGenics for the treatment of solid tumours.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-386-1mg 1mg Inquiry
GMP-Bios-ab-386-10mg 10mg Inquiry
GMP-Bios-ab-386-100mg 100mg Inquiry
GMP-Bios-ab-386-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD276;CD3E therapeutic antibody (Pre-made Obrindatamab biosimilar,Bispecific scFv with Domain Crossover)
INN Name Obrindatamab
TargetCD276;CD3E
FormatBispecific scFv with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesMacroGenics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAdvanced or Metastatic solid tumours
Development Techna